Johnson & Johnson (JNJ)vsUniverse Pharmaceuticals Inc (UPC)
JNJ
Johnson & Johnson
$273.20
-0.73%
HEALTHCARE · Cap: $615.87B
UPC
Universe Pharmaceuticals Inc
$1.49
-3.25%
HEALTHCARE · Cap: $14.47M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 559786% more annual revenue ($99.33B vs $17.74M). JNJ leads profitability with a 16.2% profit margin vs -11.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
UPC
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$273.20
$129.08 premium
Intrinsic value data unavailable for UPC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Smaller company, higher risk/reward
ROE of -39.6% — below average capital efficiency
Revenue declined 1.3%
Earnings declined 82.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : UPC
The strongest argument for UPC centers on Price/Book, Altman Z-Score, Debt/Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : UPC
The primary concerns for UPC are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while UPC is a turnaround play — different risk/reward profiles.
UPC carries more volatility with a beta of 1.68 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 29/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Universe Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Universe Pharmaceuticals INC, a pharmaceutical company, is engaged in the manufacture, marketing, distribution and sale of products derived from traditional Chinese medicine in China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?